{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011141","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.842635+00:00","generated_at":"2026-06-14T00:17:05.843286+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Editas Medicine prices $125M public offering of 12.5M shares at $10.00/share","bullets":["Offering of 12,500,000 shares at $10.00 per share; gross proceeds ~$125 million.","Underwriters granted 30-day option to purchase up to an additional 1,875,000 shares.","Net proceeds estimated at ~$117.2 million, or ~$134.9 million if option fully exercised.","Closing expected on or about June 20, 2023; J.P. Morgan, Cowen, and Evercore lead.","Proceeds will support clinical-stage genome editing pipeline development."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011141","json":"https://secwatch.observer/filing/0001558370-23-011141.json","markdown":"https://secwatch.observer/filing/0001558370-23-011141.md","text":"https://secwatch.observer/filing/0001558370-23-011141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023011141/0001558370-23-011141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023011141/edit-20230614x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:17:05.843286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47113982beb3b82f3596cb82214e7d37d697e991","claim":"Editas Medicine, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. valued at approximately $117.2 million (effective 2023-06-14).","evidence_excerpt":"On June 14, 2023, Editas Medicine, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering of 12,500,000 shares (the “Underwritten Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023011141/0001558370-23-011141-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C."},{"label":"Value","value":"approximately $117.2 million"},{"label":"Effective","value":"2023-06-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}